A signature for success

(Ludwig Institute for Cancer Research) A team led by Ludwig and Memorial Sloan Kettering researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade. Their paper, in the current issue of the New England Journal of Medicine, describes the precise genetic signatures in melanoma tumors that determine whether a patient will respond to one such therapy.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
We report on combination effects of these two promising strategies. Tumor targeting 131I-labelled anti-EGFR-antibody (Cetuximab) was used in the prototypic EGFR-expressing A431 human squamous cell carcinoma xenograft model. A 131I-labelled melanin-binding benzamide derivative was utilized targeting B16F10 melanoma in an orthotopic syngeneic C57bl6 model. Fractionated EBRT was performed using carbon ions in direct comparison with conventional photon irradiation. Tumor uptake of 131I-Cetuximab and 131I-Benzamide was enhanced by fractionated EBRT as determined by biodistribution studies. This effect was independent of radiati...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: 1 October 2018Source: Colloids and Surfaces B: Biointerfaces, Volume 170Author(s): M. Gorgizadeh, N. Azarpira, N. SattarahmadyAbstractNanothechnology-mediated photothermal therapy (PTT) is emerging as one of the inspiring alternative modality of cancer therapy that applies near-infrared radiation. High favorability of this approach is due to its minimum invasiveness, safety of non-targeted area, quick recovery, and capable simultaneous imaging. In this approach, photoabsorbing nanomaterials convert energy of infrared light to vibrational motion and generate heat. In the present study, a nanocomposite comp...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionWe report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 30 April 2018Source: Seminars in Cancer BiologyAuthor(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. EbertAbstractImmunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhi...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 November 2017Source: Seminars in Cancer BiologyAuthor(s): K. Vermaelen, A. Waeytens, O. Kholmanskikh, M. Van den Bulcke, E. Van ValckenborghAbstractImmunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a “personalized ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: 15 September 2018Source: Journal of Molecular Liquids, Volume 266Author(s): Sandhra M. Carvalho, Alexandra A.P. Mansur, Nádia S.V. Capanema, Isadora C. Carvalho, Poliane Chagas, Luiz Carlos A. de Oliveira, Herman S. MansurAbstractMalignant melanoma is the most lethal form of skin cancer in humans which is difficult to treat by conventional surgery and chemotherapeutics. Despite unquestionable progresses in recent years demonstrated by anticancer drug carriers to target tumor local microenvironment, it is growing at a rate of one million new cases being reported annually because overcoming the skin ...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Publication date: 1 October 2018Source: Colloids and Surfaces B: Biointerfaces, Volume 170Author(s): M. Gorgizadeh, N. Azarpira, N. SattarahmadyAbstractNanothechnology-mediated photothermal therapy (PTT) is emerging as one of the inspiring alternative modality of cancer therapy that applies near-infrared radiation. High favorability of this approach is due to its minimum invasiveness, safety of non-targeted area, quick recovery, and capable simultaneous imaging. In this approach, photoabsorbing nanomaterials convert energy of infrared light to vibrational motion and generate heat. In the present study, a nanocomposite comp...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | International Medicine & Public Health | Melanoma | Skin Cancer | Study